Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 25

1.

Clinical Diagnosis of Gastrointestinal Stromal Tumor (GIST): From the Molecular Genetic Point of View.

Wu CE, Tzen CY, Wang SY, Yeh CN.

Cancers (Basel). 2019 May 16;11(5). pii: E679. doi: 10.3390/cancers11050679. Review.

2.

Prospective Evaluation of Neoadjuvant Imatinib Use in Locally Advanced Gastrointestinal Stromal Tumors: Emphasis on the Optimal Duration of Neoadjuvant Imatinib Use, Safety, and Oncological Outcome.

Wang SY, Wu CE, Lai CC, Chen JS, Tsai CY, Cheng CT, Yeh TS, Yeh CN.

Cancers (Basel). 2019 Mar 25;11(3). pii: E424. doi: 10.3390/cancers11030424.

3.

TP53 mutant cell lines selected for resistance to MDM2 inhibitors retain growth inhibition by MAPK pathway inhibitors but a reduced apoptotic response.

Wu CE, Koay TS, Ho YH, Lovat P, Lunec J.

Cancer Cell Int. 2019 Mar 7;19:53. doi: 10.1186/s12935-019-0768-3. eCollection 2019.

4.

ATM Dependent DUSP6 Modulation of p53 Involved in Synergistic Targeting of MAPK and p53 Pathways with Trametinib and MDM2 Inhibitors in Cutaneous Melanoma.

Wu CE, Koay TS, Esfandiari A, Ho YH, Lovat P, Lunec J.

Cancers (Basel). 2018 Dec 20;11(1). pii: E3. doi: 10.3390/cancers11010003.

5.

Changes in and modifiable patient- and family caregiver-related factors associated with cancer patients' high self-perceived burden to others at the end of life: A longitudinal study.

Kuo SC, Chou WC, Hou MM, Wu CE, Shen WC, Wen FH, Tang ST.

Eur J Cancer Care (Engl). 2018 Nov;27(6):e12942. doi: 10.1111/ecc.12942. Epub 2018 Oct 1.

PMID:
30273990
6.

A Prognostic Model Based on Circulating Tumour Cells is Useful for Identifying the Poorest Survival Outcome in Patients with Metastatic Colorectal Cancer.

Chou WC, Wu MH, Chang PH, Hsu HC, Chang GJ, Huang WK, Wu CE, Hsieh JC.

Int J Biol Sci. 2018 Jan 12;14(2):137-146. doi: 10.7150/ijbs.23182. eCollection 2018.

7.

Response to Letter to the Editor.

Lee HF, Wu CE, Chu PH.

J Formos Med Assoc. 2018 May;117(5):456. doi: 10.1016/j.jfma.2017.12.003. Epub 2018 Feb 13. No abstract available.

8.

Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma.

Wu CE, Esfandiari A, Ho YH, Wang N, Mahdi AK, Aptullahoglu E, Lovat P, Lunec J.

Br J Cancer. 2018 Feb 20;118(4):495-508. doi: 10.1038/bjc.2017.433. Epub 2017 Dec 12.

9.

Low bone mineral density may be associated with long-term risk of cancer in the middle-aged population: A retrospective observational study from a single center.

Lee HF, Wu CE, Lin YS, Hwang JS, Wu CH, Chu PH.

J Formos Med Assoc. 2018 Apr;117(4):339-345. doi: 10.1016/j.jfma.2017.04.021. Epub 2017 May 16.

10.

Circulating Tumour Cells as an Independent Prognostic Factor in Patients with Advanced Oesophageal Squamous Cell Carcinoma Undergoing Chemoradiotherapy.

Su PJ, Wu MH, Wang HM, Lee CL, Huang WK, Wu CE, Chang HK, Chao YK, Tseng CK, Chiu TK, Lin NM, Ye SR, Lee JY, Hsieh CH.

Sci Rep. 2016 Aug 17;6:31423. doi: 10.1038/srep31423.

11.

A comparison of immunohistochemical and molecular methods used for analyzing the BRAF V600E gene mutation in malignant melanoma in Taiwan.

Huang WK, Kuo TT, Wu CE, Cheng HY, Hsieh CH, Hsieh JJ, Shen YC, Hou MM, Hsu T, Chang JW.

Asia Pac J Clin Oncol. 2016 Dec;12(4):403-408. doi: 10.1111/ajco.12574. Epub 2016 Aug 4.

PMID:
27488807
12.

Longitudinal Analysis of Severe Anxiety Symptoms in the Last Year of Life Among Patients With Advanced Cancer: Relationships With Proximity to Death, Burden, and Social Support.

Tang ST, Chen JS, Chou WC, Chang WC, Wu CE, Hsieh CH, Chiang MC, Kuo ML.

J Natl Compr Canc Netw. 2016 Jun;14(6):727-34.

PMID:
27283165
13.

Combination of palonosetron, aprepitant, and dexamethasone as primary antiemetic prophylaxis for cisplatin-based chemotherapy.

Yang CK, Wu CE, Liaw CC.

Biomed J. 2016 Feb;39(1):60-6. doi: 10.1016/j.bj.2015.08.006. Epub 2016 Mar 29.

14.

ALDH1A3, the Major Aldehyde Dehydrogenase Isoform in Human Cholangiocarcinoma Cells, Affects Prognosis and Gemcitabine Resistance in Cholangiocarcinoma Patients.

Chen MH, Weng JJ, Cheng CT, Wu RC, Huang SC, Wu CE, Chung YH, Liu CY, Chang MH, Chen MH, Chiang KC, Yeh TS, Su Y, Yeh CN.

Clin Cancer Res. 2016 Aug 15;22(16):4225-35. doi: 10.1158/1078-0432.CCR-15-1800. Epub 2016 Apr 13.

15.

Prevalence of severe depressive symptoms increases as death approaches and is associated with disease burden, tangible social support, and high self-perceived burden to others.

Tang ST, Chen JS, Chou WC, Lin KC, Chang WC, Hsieh CH, Wu CE.

Support Care Cancer. 2016 Jan;24(1):83-91. doi: 10.1007/s00520-015-2747-0. Epub 2015 May 3.

PMID:
25933701
16.

Identification of patients with hormone receptor-positive breast cancer who need adjuvant tamoxifen therapy for more than 5 years.

Wu CE, Chen SC, Chang HK, Lo YF, Hsueh S, Lin YC.

J Formos Med Assoc. 2016 Apr;115(4):249-56. doi: 10.1016/j.jfma.2015.03.003. Epub 2015 Apr 18.

17.

Cytoplasmic and nuclear parathyroid hormone-related proteins are opposing prognostic factors in patients with non-small-cell lung cancer who have undergone curative resection.

Wu CE, Wang CW, Huang WK, Yang CT, Wu YC, Hou MM, Hsieh CH, Hsieh JJ, Cheng HY, Hsu T, Chang JW.

Jpn J Clin Oncol. 2015 Mar;45(3):267-73. doi: 10.1093/jjco/hyu202. Epub 2014 Dec 5.

PMID:
25480982
18.

Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients.

Hsu CC, Wu CE, Chen JS, Tseng JH, Chiang KC, Liu YY, Tsai CY, Cheng CT, Chen TW, Jan YY, Yeh TS, Chen YY, Yeh CN.

Anticancer Res. 2014 Sep;34(9):5029-36.

PMID:
25202087
19.
20.

Prognostic factors for Taiwanese patients with cutaneous melanoma undergoing sentinel lymph node biopsy.

Wu CE, Hsieh CH, Chang CJ, Yeh JT, Kuo TT, Yang CH, Lo YF, Lin KJ, Lin YC, Chang JW.

J Formos Med Assoc. 2015 May;114(5):415-21. doi: 10.1016/j.jfma.2013.06.018. Epub 2013 Aug 19.

Supplemental Content

Loading ...
Support Center